European Centre for Disease Prevention and Control. Interim public health considerations for COVID-19 vaccination roll-out during 2023. Stockholm: ECDC; 2023 5 April 2023.

Rouvinski A, Friedman A, Kirillov S, Attal JH, Kumari S, Fahoum J, et al. Antibody response in elderly vaccinated four times with an mRNA anti-COVID-19 vaccine. Sci Rep. 2023;13(1):14165.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ravussin A, Robertson AH, Wolf AS, Blix K, Kjonstad IF, Solum G, et al. Determinants of humoral and cellular immune responses to three doses of mRNA SARS-CoV-2 vaccines in older adults: a longitudinal cohort study. Lancet Healthy Longev. 2023;4(5):e188–99.

Article  PubMed  PubMed Central  Google Scholar 

Tan NH, Geers D, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, et al. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial. Lancet Infect Dis. 2023;23(8):901–13.

Article  CAS  PubMed  Google Scholar 

Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis. 2022;22(8):1131–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Irrgang P, Gerling J, Kocher K, Lapuente D, Steininger P, Habenicht K, et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci Immunol. 2023;8(79):eade2798.

Kiszel P, Sik P, Miklos J, Kajdacsi E, Sinkovits G, Cervenak L, Prohaszka Z. Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history. Sci Rep. 2023;13(1):13166.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buhre JS, Pongracz T, Kunsting I, Lixenfeld AS, Wang W, Nouta J, et al. mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine. Front Immunol. 2022;13:1020844.

Article  CAS  PubMed  Google Scholar 

Akhtar M, Islam MR, Khaton F, Soltana UH, Jafrin SA, Rahman SIA, et al. Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations. Front Immunol. 2023;14:1309997.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshimura M, Sakamoto A, Ozuru R, Kurihara Y, Itoh R, Ishii K, et al. The appearance of anti-spike receptor binding domain immunoglobulin G4 responses after repetitive immunization with messenger RNA-based COVID-19 vaccines. Int J Infect Dis. 2024;139:1–5.

Article  CAS  PubMed  Google Scholar 

Selva KJ, Ramanathan P, Haycroft ER, Reynaldi A, Cromer D, Tan CW, et al. Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections. JCI Insight. 2023;8(18):e172470.

Kalkeri R, Zhu M, Cloney-Clark S, Plested JS, Parekh A, Gorinson D, et al. Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID Vaccines. medRxiv. 2024.

Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol. 1998;160(7):3555–61.

Article  CAS  PubMed  Google Scholar 

Frasca D, Blomberg BB. Effects of aging on B cell function. Curr Opin Immunol. 2009;21(4):425–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carballo I, Alvela L, Perez LF, Gude F, Vidal C, Alonso M, et al. Serum Concentrations of IgG4 in the Spanish Adult Population: Relationship with Age, Gender, and Atopy. PLoS ONE. 2016;11(2): e0149330.

Article  PubMed  PubMed Central  Google Scholar 

Verheul MK, Nijhof KH, de Zeeuw-Brouwer ML, Duijm G, Ten Hulscher H, de Rond L, et al. Booster Immunization Improves Memory B Cell Responses in Older Adults Unresponsive to Primary SARS-CoV-2 Immunization. Vaccines (Basel). 2023;11(7):1196.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Neut KM, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317(5844):1554–7.

Article  Google Scholar 

Rispens T, Huijbers MG. The unique properties of IgG4 and its roles in health and disease. Nat Rev Immunol. 2023;23(11):763–78.

Article  CAS  PubMed  Google Scholar 

Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.

Article  PubMed  PubMed Central  Google Scholar 

Gorman MJ, Patel N, Guebre-Xabier M, Zhu AL, Atyeo C, Pullen KM, et al. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. Cell Rep Med. 2021;2(9): 100405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ullah I, Prevost J, Ladinsky MS, Stone H, Lu M, Anand SP, et al. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity. 2021;54(9):2143–58 e15.

Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Chong Z, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021;184(7):1804-20 e16.

Kaplonek P, Cizmeci D, Kwatra G, Izu A, Lee JS, Bertera HL, et al. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19. Nat Immunol. 2023;24(7):1161–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest. 2013;123(5):2183–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bartsch YC, Cizmeci D, Kang J, Zohar T, Periasamy S, Mehta N, et al. Antibody effector functions are associated with protection from respiratory syncytial virus. Cell. 2022;185(26):4873–86 e10.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, et al. Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell. 2018;174(4):938–52 e13.

Zohar T, Hsiao JC, Mehta N, Das J, Devadhasan A, Karpinski W, et al. Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates. Cell Host Microbe. 2022;30(1):41–52 e5.

Ullah I, Beaudoin-Bussieres G, Symmes K, Cloutier M, Ducas E, Tauzin A, et al. The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. Cell Rep Med. 2023;4(1): 100893.

Article  CAS  PubMed  Google Scholar 

Zhang A, Stacey HD, D’Agostino MR, Tugg Y, Marzok A, Miller MS. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat Rev Immunol. 2023;23(6):381–96.

Article  CAS  PubMed  Google Scholar 

van Erp EA, Luytjes W, Ferwerda G, van Kasteren PB. Fc-Mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019;10:548.

Article  PubMed  PubMed Central  Google Scholar 

van den Hoogen LL, Boer M, Postema A, de Rond L, de Zeeuw-Brouwer ML, Pronk I, et al. Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands. Vaccines (Basel). 2022;10(9):1480.

Article  PubMed  PubMed Central  Google Scholar 

den Hartog G, Schepp RM, Kuijer M, GeurtsvanKessel C, van Beek J, Rots N, et al. SARS-CoV-2-specific antibody detection for seroepidemiology: A multiplex analysis approach accounting for accurate seroprevalence. J Infect Dis. 2020;222(9):1452–61.

Article  Google Scholar 

Gelderloos AT, Lakerveld AJ, Schepp RM, Nicolaie MA, van Beek J, Beckers L, et al. Primary SARS-CoV-2 infection in children and adults results in similar Fc-mediated antibody effector function patterns. Clin Transl Immunology. 2024;13(8): e1521.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM, et al. Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities. Front Immunol. 2017;8:877.

Article  PubMed  PubMed Central  Google Scholar 

Van Coillie J, Pongracz T, Rahmoller J, Chen HJ, Geyer CE, van Vught LA, et al. The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees. EBioMedicine. 2023;87: 104408.

Article  PubMed  Google Scholar 

Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278(5):3466–73.

Article